You are here: Industry Insights > Wuxi Biologics

News List

WuXi Biologics Continues to Deliver Record Results en-cphi.cn
March 19, 2019
WuXi Biologics announces its audited annual results for the year ended December 31, 2018 today.
WuXi Biologics Congratulates Amicus on Receiving FDA Breakthrough Therapy Designation for AT-GAA en-cphi.cn
March 01, 2019
The second product successfully receiving Breakthrough Therapy Designation that WuXi Biologics has enabled its partner to develop
ABL Bio Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Novel Immune Check Point Bispecifics for $220 Million en-cphi.cn
March 01, 2019
WuXi Biologics and ABL Bio Corporation announced the expansion of their strategic partnership for novel bispecific antibodies and immune-oncology program.
EMA Completed Pre-Approval Inspection of cGMP DS and DP Facilities for Trogarzo™ at WuXi Biologics en-cphi.cn
February 19, 2019
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery
WuXi Biologics and Amicus Sign Exclusive Manufacturing Partnership Wuxi Biologics
February 12, 2019
WuXi Biologics and Amicus Therapeutics announced that the companies have entered into an exclusive commercial manufacturing partnership for Amicus' Pompe biologic ATB200.
Flourishing WuXi Biologics in talks to make vaccines for scandal-hit China: report fiercepharma
January 24, 2019
WuXi Biologics has been surfing a surge of growth in biologic drugs, but the contract manufacturer isn't just interested in novel medications. It's also eyeing an older type of therapy: vaccines, which have come under special scrutiny in China lately.
CANbridge Pharmaceuticals expands partnership with Wuxi Biologics pharmaceutical-technology
January 11, 2019
China’s CANbridge Pharmaceuticals has expanded its alliance with WuXi Biologics for the discovery, development and commercialisation of four additional drug candidates to potentially treat rare genetic chronic diseases.....
WuXi Biologics and AC Immune to Establish an Exclusive Strategic Partnership en-cphi.cn
December 20, 2018
WuXi Biologics and AC Immune SA announced the first steps of an exclusive strategic collaboration that covers biologics discovery, development and manufacturing.
WuXi Biologics Congratulates Tychan on First-in-Class Monoclonal Antibody for Yellow Fever after Record 7 Months of Development en-cphi.cn
December 13, 2018
WuXi Biologics congratulates its partner Tychan for dosing of first individual in phase 1 trial of TY
Oxford BioTherapeutics, WuXi Biologics team up to create cancer antibodies pharmatimes
December 13, 2018
Oxford BioTherapeutics has entered a strategic partnership with WuXi Biologics to develop bispecific antibodies for the treatment of several cancer types, expanding on the existing collaboration between the two.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page